Sensus Healthcare, Inc.

DB:5TX Stock Report

Market Cap: €108.7m

Sensus Healthcare Valuation

Is 5TX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5TX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€23.15
Fair Value
71.9% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: 5TX (€6.5) is trading below our estimate of fair value (€23.15)

Significantly Below Fair Value: 5TX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5TX?

Key metric: As 5TX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 5TX. This is calculated by dividing 5TX's market cap by their current earnings.
What is 5TX's PE Ratio?
PE Ratio12x
EarningsUS$9.31m
Market CapUS$111.94m

Price to Earnings Ratio vs Peers

How does 5TX's PE Ratio compare to its peers?

The above table shows the PE ratio for 5TX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.4x
PUS PULSION Medical Systems
26.2xn/a€131.9m
SBS Stratec
35.3x25.4%€361.6m
DRW3 Drägerwerk KGaA
8.1x1.2%€855.2m
EUZ Eckert & Ziegler
28.1x5.2%€1.0b
5TX Sensus Healthcare
12x26.0%€111.9m

Price-To-Earnings vs Peers: 5TX is good value based on its Price-To-Earnings Ratio (12x) compared to the peer average (24.8x).

Price to Earnings Ratio vs Industry

How does 5TX's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
5TX 12.0xIndustry Avg. 31.1xNo. of Companies9PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 5TX is good value based on its Price-To-Earnings Ratio (12x) compared to the European Medical Equipment industry average (30.7x).

Price to Earnings Ratio vs Fair Ratio

What is 5TX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5TX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12x
Fair PE Ratio27.3x

Price-To-Earnings vs Fair Ratio: 5TX is good value based on its Price-To-Earnings Ratio (12x) compared to the estimated Fair Price-To-Earnings Ratio (27.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 5TX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.50
€11.04
+69.9%
13.0%€13.44€9.60n/a4
Jan ’26€6.90
€11.04
+60.1%
13.0%€13.44€9.60n/a4
Dec ’25€8.05
€11.04
+37.2%
13.0%€13.44€9.60n/a4
Nov ’25€5.85
€9.57
+63.5%
8.2%€10.93€9.11n/a4
Oct ’25€5.10
€9.77
+91.6%
8.8%€10.99€9.16n/a3
Sep ’25€5.75
€9.77
+69.9%
8.8%€10.99€9.16n/a3
May ’25€3.12
€6.92
+121.9%
6.7%€7.38€6.46n/a2
Apr ’25€3.54
€6.46
+82.5%
11.7%€7.39€5.54n/a3
Mar ’25€3.74
€6.61
+76.7%
10.4%€7.42€5.56n/a4
Feb ’25€2.96
€5.53
+87.1%
26.4%€7.38€3.69n/a4
Jan ’25€2.14
€5.03
+134.6%
27.3%€7.32€3.66€6.904
Dec ’24€2.18
€5.05
+132.3%
25.1%€7.49€3.74€8.055
Nov ’24€2.03
€6.93
+240.9%
6.4%€7.30€6.39€5.855
Oct ’24€2.46
€6.93
+182.1%
6.4%€7.30€6.39€5.105
Sep ’24€2.82
€6.93
+146.1%
6.4%€7.30€6.39€5.755
Aug ’24€2.69
€7.44
+177.0%
11.9%€9.08€6.36€5.805
Jul ’24€2.96
€7.44
+151.7%
11.9%€9.08€6.36€4.885
Jun ’24€2.47
€7.44
+201.2%
11.9%€9.08€6.36€5.155
May ’24€4.22
€13.87
+228.7%
20.4%€18.62€10.24€3.125
Apr ’24€4.64
€13.87
+199.0%
20.4%€18.62€10.24€3.545
Mar ’24€6.40
€13.87
+116.7%
20.4%€18.62€10.24€3.745
Feb ’24€8.30
€14.27
+71.9%
19.6%€18.53€10.19€2.965
Jan ’24€6.95
€15.36
+121.0%
20.2%€20.07€11.04€2.145
Analyst Price Target
Consensus Narrative from 4 Analysts
€10.94
Fair Value
40.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 19:38
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sensus Healthcare, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Alexander NowakCraig-Hallum Capital Group LLC
Ilya ZubkovFreedom Broker